AMAL Therapeutics, a Swiss biotech developing peptide-based therapeutic cancer vaccines, has entered into a collaborative agreement with Boehringer Ingelheim under which AMAL will conduct a Phase Ib study, (KISIMA-01), to evaluate the combination of its lead candidate, ATP128, with Boehringer’s anti-PD1 compound, BI754091, in Microsatellite Stable (MSS) patients with stage IV colorectal cancer.   AMAL’s lead candidate, ATP128, is a chimeric recombinant protein designed using AMAL’s proprietary...